Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes

被引:59
作者
MacIsaac, Richard J. [1 ,2 ]
Jerums, George [2 ]
机构
[1] St Vincents Hosp, Dept Endocrinol & Diabet, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Fitzroy, Vic 3065, Australia
关键词
Glucose control; Cardiovascular disease; Diabetes; Mortality; ALL-CAUSE MORTALITY; DISEASE RISK; LIFE-STYLE; MELLITUS; COMPLICATIONS; HYPERGLYCEMIA; POPULATION; OBESITY;
D O I
10.1016/j.hlc.2010.07.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Numerous observational studies have clearly shown a relationship between hyperglycaemia and cardiovascular (CV) disease. However, the United Kingdom Prospective Diabetes Study (UKPDS), which involved subjects with newly diagnosed type 2 diabetes, just failed to show that intensive glucose control significantly reduces CV events. The results of three subsequent large randomised controlled trials, the Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) and the Veterans Administration Diabetes Trial (VADT), that involved approximately 25,000 subjects with established type 2 diabetes also failed to show that intensive glucose control, aiming for a glycated haemoglobin (HbA(1c)) level < 7%, significantly reduces CV events. The ACCORD trial even suggested that under certain circumstances, intensive glucose control is associated with an increased risk for CV and all-cause mortality. Although the exact mechanisms responsible for an increase in mortality in the ACCORD trial remain unknown, there was an association between increased rates of mortality with higher rates of severe hypoglycaemia in the intensive glucose control group. In contrast, a 10-year post-randomisation follow-up study of the tight glucose intervention arm of the UKPDS showed that intensive glucose control was associated with a significant reduction in the risk for myocardial infarction (MI), diabetes-related deaths and all-cause mortality. This suggests that early strict glucose control generates a legacy effect that is eventually translated into protection from CV events. Recent meta-analyses of the above randomised trails have also shown that intensive glucose control is associated with a reduced risk of MI, without a clear benefit on other CV diseases such as stroke. Furthermore, these analyses have also shown that intensive glucose control is associated with increased rates of severe hypoglycaemia but not increased rates of CV or all-cause mortality. Aiming for HbA(1c) levels of <7.0% still remains the general target for good glucose control. Under certain circumstances, aiming for lower HbA(1c) levels may be appropriate. This applies in the setting of newly diagnosed diabetes in relatively young individuals without significant co-morbidities and in patients treated with agents that minimise the risk of severe hypoglycaemia such as metformin. Whether this also applies to newer glucose-lowering agents that target the incretin system will depend on CV outcomes of long-term studies which are in progress. (Heart, Lung and Circulation 2011;20:647-654) (C) 2010 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:647 / 654
页数:8
相关论文
共 27 条
[1]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]  
[Anonymous], NEW ENGL J MED
[3]   Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study [J].
Barr, E. L. M. ;
Boyko, E. J. ;
Zimmet, P. Z. ;
Wolfe, R. ;
Tonkin, A. M. ;
Shaw, J. E. .
DIABETOLOGIA, 2009, 52 (03) :415-424
[4]   Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance - The Australian diabetes, obesity, and lifestyle study (AusDiab) [J].
Barr, Elizabeth L. M. ;
Zimmet, Paul Z. ;
Welborn, Timothy A. ;
Jolley, Damien ;
Magliano, Dianna J. ;
Dunstan, David W. ;
Cameron, Adrian J. ;
Dwyer, Terry ;
Taylor, Hugh R. ;
Tonkin, Andrew M. ;
Wong, Tien Y. ;
McNeil, John ;
Shaw, Jonathan E. .
CIRCULATION, 2007, 116 (02) :151-157
[5]   Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail [J].
Brasacchio, Daniella ;
Okabe, Jun ;
Tikellis, Christos ;
Balcerczyk, Aneta ;
George, Prince ;
Baker, Emma K. ;
Calkin, Anna C. ;
Brownlee, Michael ;
Cooper, Mark E. ;
El-Osta, Assam .
DIABETES, 2009, 58 (05) :1229-1236
[6]   Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus [J].
Cheung, N. Wah ;
Conn, Jennifer J. ;
d'Emden, Michael C. ;
Gunton, Jenny E. ;
Jenkins, Alicia J. ;
Ross, Glynis P. ;
Sinha, Ashim K. ;
Andrikopoulos, Sofianos ;
Colagiuri, Stephen ;
Twigg, Stephen M. .
MEDICAL JOURNAL OF AUSTRALIA, 2009, 191 (06) :339-344
[7]   Full Accounting of Diabetes and Pre-Diabetes in the US Population in 1988-1994 and 2005-2006 [J].
Cowie, Catherine C. ;
Rust, Keith F. ;
Ford, Earl. S. ;
Eberhardt, Mark S. ;
Byrd-Holt, Danita D. ;
Li, Chaoyang ;
Williams, Desmond E. ;
Gregg, Edward W. ;
Bainbridge, Kathleen E. ;
Saydah, Sharon H. ;
Geiss, Linda S. .
DIABETES CARE, 2009, 32 (02) :287-294
[8]   Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study [J].
Currie, Craig J. ;
Peters, John R. ;
Tynan, Aodan ;
Evans, Marc ;
Heine, Robert J. ;
Bracco, Oswaldo L. ;
Zagar, Tony ;
Poole, Chris D. .
LANCET, 2010, 375 (9713) :481-489
[9]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[10]   Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [J].
Duckworth, William ;
Abraira, Carlos ;
Moritz, Thomas ;
Reda, Domenic ;
Emanuele, Nicholas ;
Reaven, Peter D. ;
Zieve, Franklin J. ;
Marks, Jennifer ;
Davis, Stephen N. ;
Hayward, Rodney ;
Warren, Stuart R. ;
Goldman, Steven ;
McCarren, Madeline ;
Vitek, Mary Ellen ;
Henderson, William G. ;
Huang, Grant D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :129-U62